Pharmacological inhibition of apical sodium-dependent bile acid transporter changes bile composition and blocks progression of sclerosing cholangitis in multidrug resistance 2 knockout mice.
about
Recent advances in understanding and managing cholestasisTargeting the Enterohepatic Bile Acid Signaling Induces Hepatic Autophagy via a CYP7A1-AKT-mTOR Axis in Mice.Emerging drugs for the treatment of Primary Biliary Cholangitis.Emerging treatments for primary sclerosing cholangitis.Emerging pharmacologic therapies for primary sclerosing cholangitis.Current and future therapies for inherited cholestatic liver diseases.Hepatic MDR3 expression impacts lipid homeostasis and susceptibility to inflammatory bile duct obstruction in neonates.The characteristics of activated portal fibroblasts/myofibroblasts in liver fibrosis.The ascending pathophysiology of cholestatic liver disease.New therapeutic concepts in bile acid transport and signaling for management of cholestasis.Bile Acid Uptake Transporters as Targets for Therapy.Old and new treatments for primary biliary cholangitis.Pregnancy and bile acid disorders.Inhibition of ileal bile acid uptake protects against nonalcoholic fatty liver disease in high-fat diet-fed mice.Toxic bile and sclerosing cholangitis: Is there a role for pharmacological interruption of the bile acid enterohepatic circulation?New therapies target the toxic consequences of cholestatic liver disease.Liver transplantation for decompensated liver cirrhosis caused by progressive familial intrahepatic cholestasis type 3: A case report.Role of gut microbiota and oxidative stress in the progression of non-alcoholic fatty liver disease to hepatocarcinoma: Current and innovative therapeutic approaches.Cenicriviroc, a cytokine receptor antagonist, potentiates all-trans retinoic acid in reducing liver injury in cholestatic rodents.BILIARY ATRESIA: Clinical and Research Challenges for the 21st Century.Colesevelam attenuates cholestatic liver and bile duct injury in Mdr2-/- mice by modulating composition, signalling and excretion of faecal bile acids.Investigational drugs in phase II clinical trials for primary biliary cholangitis.Sustained activation of detoxification pathways promotes liver carcinogenesis in response to chronic bile acid-mediated damage.Macrophage-derived IL-1β/NF-κB signaling mediates parenteral nutrition-associated cholestasis.Primary Sclerosing CholangitisIleal Bile Acid Transporter Inhibition for the Treatment of Chronic Constipation, Cholestatic Pruritus, and NASHJaundice revisited: recent advances in the diagnosis and treatment of inherited cholestatic liver diseasesProgressive familial intrahepatic cholestasis: diagnosis, management, and treatment
P2860
Q26748537-FB61B7F5-B570-450E-90F2-6B22C6D7E1EEQ37673664-CCD604F7-B81A-4807-AEC4-1F764F9A4395Q38744215-3DA6F668-3CA6-4B97-8AFF-B99BF42C2E43Q38748384-34191A68-AE7D-452F-A1F3-8643A4C990C8Q38751076-679C4910-184D-43C8-A773-ABFB4000B74EQ38754736-66BEB6E2-0FD7-410F-8CA1-CE87E9068C04Q38869131-AC9C9059-9346-4A2F-95C6-26348086998BQ38945443-3DAD21D8-1FD0-4E80-8EE2-4403F5CE0AD8Q39040911-811BE995-5BE2-4995-9BD2-97A8429083C2Q39044702-6604EBD6-BB6E-4BE9-8800-E5052B9B1F5AQ39156569-0789729D-2421-4C98-92D8-7B4023E87536Q39216355-5013B98D-7361-4542-A6EF-7DDBA6708381Q39267976-A7187779-404A-4F4A-869D-E691EA849A59Q41382617-EA19AE86-32F5-4923-952E-949C3562E7B2Q42686933-E730B15B-9308-4AA4-8ACE-6E3FE1EF2C53Q47223909-2EAD94EA-276F-4618-8F23-97AD9AA1F406Q49487699-DF04CA0C-51BA-47FA-98B6-C77CD6978E07Q50136712-51CEB169-FD16-40BC-A295-FC8DEDFE7607Q51759923-8D8637E7-4787-4DBC-91D5-12444616067FQ52617019-6AF183D0-BCE7-4244-A521-92CB738C6459Q52720224-279A6460-096C-4FC1-B50F-2AA40885D2FCQ53098304-D7B1E8C9-F55F-42A7-9A48-13B7F81FAD3AQ55238642-BF1E6601-B961-4EA3-A8F9-FFADAE983E4AQ55408026-64FAB7D1-DECA-40F2-BCE5-F0380FDFCCBEQ56442935-F7736BC3-5F4E-48CA-8B31-12753C566F5CQ57099106-FAF1D36F-8D28-426E-9F87-C0979E2C2EFAQ58114687-473A064C-9B6D-4CB2-89D3-F7D1D731D183Q58754600-0FA59D4D-0B6F-4C2A-83F2-3D2664557331
P2860
Pharmacological inhibition of apical sodium-dependent bile acid transporter changes bile composition and blocks progression of sclerosing cholangitis in multidrug resistance 2 knockout mice.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Pharmacological inhibition of ...... ug resistance 2 knockout mice.
@ast
Pharmacological inhibition of ...... ug resistance 2 knockout mice.
@en
type
label
Pharmacological inhibition of ...... ug resistance 2 knockout mice.
@ast
Pharmacological inhibition of ...... ug resistance 2 knockout mice.
@en
prefLabel
Pharmacological inhibition of ...... ug resistance 2 knockout mice.
@ast
Pharmacological inhibition of ...... ug resistance 2 knockout mice.
@en
P2093
P2860
P921
P356
P1433
P1476
Pharmacological inhibition of ...... rug resistance 2 knockout mice
@en
P2093
Alexander G Miethke
Amy E Taylor
Bradley T Keller
Celine S Lages
Julia Simmons
Kenneth D R Setchell
Rebekah Karns
Shana White
Shiva Kumar Shanmukhappa
Stephenson Nkinin
P2860
P304
P356
10.1002/HEP.27973
P407
P577
2015-08-21T00:00:00Z